The market is expected to rise as a result of the rising incidence of vasomotor and menopausal symptoms such as hot flashes and night sweats, among women going through the menopausal transition. Menopause is also connected to conditions such as depression, mood changes, and difficulties concentrating. According to a study that was published in the International Journal of Applied & Basic Medical Research, around 87.7% of women who reported menopausal symptoms, 36.7% of women said they experienced hot flashes. Anxiety accounted for 80% of the reported symptoms, and sleep problems accounted for 61.2%. Thus, these factors propel the market growth during the forecast period.
Data Bridge Market Research analyses that the Menopausal Disorder Treatment Market is expected to grow at a CAGR of 7.90% in the forecast period of 2022 to 2029 and is expected to reach USD 21,790.13 million by 2029 from USD 11,860.10 million in 2021.
Advancements in Clinical Trials Are Expected to Drive the Market
The developments in menopausal disorder treatment drugs' clinical trials will be positive for the businesses competing in the market. Several significant businesses have advanced ongoing clinical trials. A clinical trial funded by Senju Pharmaceutical Co., Ltd. and titled "A Study to Assess the Safety and Effectiveness of SJP-0035 for Treatment of Patients with Menopausal disorder treatment" made progress in April 2019. It is presently in phase 3 of the trial. Such improvements in medication trials directly affected the market's expansion during the next few years.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Stages (Menopause, Postmenopause, Perimenopause), Type (Hormonal Therapy and Non-Hormonal Therapy), Menopause Symptoms (Vasomotor Symptoms, Atrophic Vaginitis, Osteoporosis, Joint Pain, Weight Gain, Dyspareunia, Depression, Others), Dosage Form (Tablet, Creams, Gels, Rings/Insert, Patch/Film, Injection Shot, Spray, Others), Route of Administration (Oral, Vaginal, Transdermal, Parenteral), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Dr. Reddy's Laboratories Ltd. (Hyderabad), Mylan N.V. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Eli Lilly and Company (U.S.), Allergan (Ireland), Novo Nordisk A/S, Novartis AG (Switzerland), Abbott (U.S.), TherapeuticsMD, Inc. (U.S.), Ipsen Pharma (France), Besins Healthcare (Belgium), Mithra Pharmaceuticals (Belgium), Aché Laboratórios Farmacêuticos S.A (Brazil), SEBELA PHARMACEUTICALS (U.S.), Fervent Pharmaceuticals Inc. (U.S.), KaNDy Therapeutics (U.K.), Duchesnay USA (U.S.), Novo Nordisk A/S (Denmark)
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
Global menopausal disorder treatment market is categorized into seven notable segments which are based on stages, type, menopause symptoms, dosage form, route of administration, end-user and distribution channel.
- On the basis of stages, the global menopausal disorder treatment market is segmented into perimenopause, menopause and postmenopause.
Menopause segment is expected to dominate the menopausal disorder treatment market
Menopause segment is expected to dominate the market with 44.75% market share because of rising older female population across the globe facing the menopause phase.
- On the basis of type, the global menopausal disorder treatment market is segmented into hormonal therapy and non-hormonal therapy. Hormonal therapy segment is expected to dominate the market with 81.22% market share because of ability to reduce menopausal symptoms such as hot flushes and vaginal dryness in women.
- On the basis of menopause symptoms, the global menopausal disorder treatment market is segmented into vasomotor symptoms, atrophic vaginitis, dyspareunia, osteoporosis, depression, joint pain, weight gain and others.
Vasomotor symptoms segment is expected to dominate the menopausal disorder treatment market
Vasomotor symptoms segment is expected to dominate the market with 27.24% market share because these symptoms are the primary symptoms which are diagnosed for the menopause in females. Moreover, most of the market players are engaged in the research and development of innovative drugs which can treat hot flushes and other vasomotor symptoms.
- On the basis of dosage form, the global menopausal disorder treatment market is segmented into tablet, cream, gels, patch/film, rings/inserts, spray, injection shot and others. Tablet segment is expected to dominate the market with 353.46% market share because of increased bioavailability; provide prolonged stability to medicaments and large number of products used for the treatment of menopause associated disorders is present in tablets form.
- On the basis of route of administration, the global menopausal disorder treatment market is segmented into oral, parenteral, transdermal and vaginal. Oral segment is expected to dominate the market with 45.36% market share because it is convenient to the patients and do not required professional person for the administration. Moreover, a large number of formulations are presents in tablet/capsule form.
- On the basis of end user, the global menopausal disorder treatment market is segmented into hospital, clinics and home healthcare. Hospital segment is expected to dominate the market with 42.62% market share because hospitals are the first or primary place for the diagnosis and treatment of menopause or related symptoms.
- On the basis of distribution channel, the global menopausal disorder treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy. Hospital pharmacy segment is expected to dominate the market with 43.22% market share because hospital pharmacies have the various numbers of products according to the patient need.
Major Players
Data Bridge Market Research recognizes the following companies as the major menopausal disorder treatment market players in menopausal disorder treatment market are Dr. Reddy's Laboratories Ltd. (Hyderabad), Mylan N.V. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Eli Lilly and Company (U.S.), Allergan (Ireland), Novo Nordisk A/S, Novartis AG (Switzerland), Abbott (U.S.), and TherapeuticsMD, Inc. (U.S.).
Market Development
- In 2020, Bayer acquired the UK-based biotech KaNDy Therapeutics Ltd. to increase the number of drugs under development for the treatment of women. In accordance with the settlement's terms, Bayer make an upfront payment of USD 425 million (or roughly 560 million Canadian dollars), potential milestone payments of up to USD 450 million (or roughly 600 million Canadian dollars), and potential additional triple digit million dollar sales milestone payments.
- In 2020, Wanbury acquired four important brands of Cipla, allowing Cipla to expand its market share in the women's health sector. The nutraceutical remedies, which offered under four umbrella brands and deal with a range of health problems brought on by dietary deficiencies or excesses.
Regional Analysis
Geographically, the countries covered in the menopausal disorder treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in menopausal disorder treatment market in the forecast period 2022 - 2029
North America is dominating because of the existence of significant key players and an advanced healthcare infrastructure. In addition the rising number of elderly females in the United States is also helping the region to maintain its dominance in the market.
Asia-Pacific is estimated to be the fastest growing region in menopausal disorder treatment market in the forecast period 2022 - 2029
Asia-Pacific is expected to grow during the forecast period of 2022 to 2029due to the rising incidence of menopausal disorders and rising number of R&D activities. The menopausal category has taken over the Japanese market due to the ongoing expansion of research and development activities.
COVID-19 Impact Analysis
The World Health Organization (WHO) has declared the COVID-19 virus a public health emergency as a result of its global spread since its discovery in December 2019. The cause of the pneumonia cases was determined to be COVID-19, a brand-new coronavirus. The rapid global spread of this virus resulted in a significant number of fatalities. The World Health Organization (WHO) declared COVID-19 a global pandemic in March 2020 and advised strict action to stop the disease's spread. Since then, the pandemic has slowed down healthcare industry growth and messed up the supply chain. In order to stop the spread of COVID-19, governments in numerous countries have also implemented nationwide lockdowns. Similar challenges are being faced by healthcare businesses around the world that are trying to maintain supply chain operations.
For more detailed information about the menopausal disorder treatment market report, click here – https://www.databridgemarketresearch.com/es/reports/global-menopausal-disorder-treatment-market
